

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/22946

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01N 43/40, 43/42; A61K 31/47, 31/445; C07J 31/00, 41/00, 9/00
US CL : 514/314, 317, 822; 552/550

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/314, 317, 822; 552/550

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EAST (USPATS, USGPUB, USOCR), CAPLUS, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SMYTHE, M.A., et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. American Journal of Hematology, 2002, Vol. 71, pages 50-52, especially p.52.	1-13
X	KONDO, L.M., et al. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Annals of Pharmacotherapy, April 2001, Vol 35, pages 440-451, especially pages 442 and 446.	1, 3-13
X	ADKINS, J.C., et al. Lepirudin: a review of its potential place in the management of thrombotic disorders. BioDrugs. September 1998, Vol. 10, No.3, pages 227-255, especially p. 228, 232-233, 239-241, 247, and 249-251.	1-5, 7-9
X — Y	LAPOSATA, M.L., et al. College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Archives of Pathology and Laboratory Medicine. September 1998, Vol. 122, No. 9, pages 799-807, especially pages 801 and 804-805.	1-9 ----- 10-13



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent published on or after the international filing date
"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

18 January 2005 (18.01.2005)

Date of mailing of the international search report

15 MAR 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Lora E Barnhart

Telephone No. 571-272-1600

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/22946

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HURSTING, M.J. et al. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clinical Chemistry. 1999, Vol. 45, No. 3, pages 409-412, especially p. 411.	1-13

Box No. VIII(iv) "DECLARATION OF INVENTORSHIP (only for the purposes of the designation of the United States of America). The declaration must conform to the following standardized wording provided for in Section 214; see Notes to Boxes Nos. VIII, VIII(I) to (v) (in general) and the specific Notes to Box No. VIII (iv). If this Box is not used, this sheet should not be included in the request.

**Declaration of Inventorship (Rules 4.17(iv) and 51bis.1(a)(iv))
for the purposes of the designation of the United States of America:**

I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought.

This declaration is directed to the international application of which it forms a part (if filing declaration with application).

This application is directed to international application No. PCT/ (if furnishing declaration pursuant to Rule 26ter).

I hereby declare that my residence, mailing address, and citizenship are as stated next to my name.

I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Application," by application number, country or Member of the World Trade Organization, day, month and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.

Prior Applications: (prior to priority).....

I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name: **Margaret M. GARDNER**

Residence: One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101, United States of America

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America and Italy

Inventor's Signature: Margaret Gardner
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 7/15/04
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: **Marcie J. HURSTING**

Residence: 11329 Berger Terrace, Potomac, Maryland 20854, United States of America

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America

Inventor's Signature: Marcie J. Hursting
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 7/13/04
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

☒ This declaration is continued on the following sheet, "Continuation of Box No. VIII(iv)".

Continuation of Box No. VIII(i) to (v) Declaration

If the space is insufficient in any of Boxes Nos. VIII(i) to (v) to furnish all the information, including in the case where more than two inventors are to be named in Box No. VIII (iv), in such case, write "Continuation of Box No. VIII " (indicate the item number of the Box) and furnish the information in the same manner as required for the purposes of the Box in which the space was insufficient. If additional space is needed in respect of two or more declarations, a separate continuation box must be used for each such declaration. If this Box is not used, this sheet should not be included in the request.

Name: Elizabeth A. TARKA

Residence: 2301 Renaissance Blvd., King of Prussia, Pennsylvania 19406, United States of America

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America

Inventor's Signature: Elizabeth A. Tarka
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 7/15/04
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: Catherine N. VERME-GIBBONEY

Residence: One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101, United States of America

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America

Inventor's Signature: _____
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: _____
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Continuation of Box No. VIII (v) to (v) Declaration

PCT/US2004/022946

If the space is insufficient in any of Boxes Nos. VIII (I) to (v) to furnish all the information, including in the case where more than two inventors are to be named in Box No. VIII (iv), in such case, write "Continuation of Box No. VIII" (indicate the item number of the Box) and furnish the information in the same manner as required for the purposes of the Box in which the space was insufficient. If additional space is needed in respect of two or more declarations, a separate continuation box must be used for each such declaration. If this Box is not used, this sheet should not be included in the request.

Name: **Elizabeth A. TARKA**

Residence: 2301 Renaissance Blvd., King of Prussia, Pennsylvania 19406, United States of America

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America

Inventor's Signature: _____
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: _____
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: **Catherine N. VERME-GIBBONEY**

Residence: One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101, United States of America

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America

Inventor's Signature: Catherine Verme-Gibboney
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 7/15/04
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)